Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mary Jane Masson Hinrichs
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
Cancer Cell
Cancer Research
Oncology
Cell Biology
Related publications
Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors
Cancer Discovery
Oncology
Antibody-Drug Conjugates With HER2-targeting Antibodies From Synthetic Antibody Libraries Are Highly Potent Against HER2-positive Human Gastric Tumor in Xenograft Models
mAbs
Allergy
Immunology
Targeted Delivery of Doxorubicin to HER2 Positive Tumor Models
International Journal of Nanomedicine
Organic Chemistry
Biophysics
Biomaterials
Pharmaceutical Science
Medicine
Bioengineering
Drug Discovery
Nanoscience
Nanotechnology
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
HER2 Signaling Modulates the Equilibrium Between Pro- And Antiangiogenic Factors via Distinct Pathways: Implications for HER2-targeted Antibody Therapy
Oncogene
Cancer Research
Genetics
Molecular Biology
The Latest Research and Development Into the Antibody–Drug Conjugate, [Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Chemical and Pharmaceutical Bulletin
Medicine
Drug Discovery
Chemistry
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Clinical Cancer Research
Cancer Research
Oncology
Tumor Stroma–targeted Antibody-Drug Conjugate Triggers Localized Anticancer Drug Release
Journal of Clinical Investigation
Medicine
